What is Coeptis Therapeutics Holdings Inc's earnings per share (EPS)?

Coeptis Therapeutics Holdings Inc (COEPW) reported diluted earnings per share of $-5.65 for fiscal year 2024. This represents a 65.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Coeptis Therapeutics Holdings Inc Financials

COEPW

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Coeptis Therapeutics Holdings Inc (COEPW) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

3/9

Coeptis Therapeutics Holdings Inc passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Low Quality

0.61x

For every $1 of reported earnings, Coeptis Therapeutics Holdings Inc generates $0.61 in operating cash flow (-$6.6M OCF vs -$10.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-25.4x

Coeptis Therapeutics Holdings Inc earns $-25.4 in operating income for every $1 of interest expense (-$10.1M vs $396K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

Coeptis Therapeutics Holdings Inc generated $0 in revenue in fiscal year 2024.

EBITDA

-$9.1M

YoY+55.8%

Coeptis Therapeutics Holdings Inc's EBITDA was -$9.1M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 55.8% from the prior year.

Net Income

-$10.9M

YoY+48.9%

Coeptis Therapeutics Holdings Inc reported -$10.9M in net income in fiscal year 2024. This represents an increase of 48.9% from the prior year.

EPS (Diluted)

$-5.65

YoY+65.9%

Coeptis Therapeutics Holdings Inc earned $-5.65 per diluted share (EPS) in fiscal year 2024. This represents an increase of 65.9% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$533K

YoY-63.7%

5Y CAGR+302.4%

Coeptis Therapeutics Holdings Inc held $533K in cash against $150K in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

YoY+19.8%

Coeptis Therapeutics Holdings Inc had 2M shares outstanding in fiscal year 2024. This represents an increase of 19.8% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-321.6%

YoY+2291.1pp

5Y CAGR-307.4pp

Coeptis Therapeutics Holdings Inc's ROE was -321.6% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is up 2291.1 percentage points from the prior year.

Capital Allocation

R&D Spending

$2.3M

YoY-65.0%

Coeptis Therapeutics Holdings Inc invested $2.3M in research and development in fiscal year 2024. This represents a decrease of 65.0% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

COEPW Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	$0	$0	$0-100.0%	$75K	N/A	N/A
Cost of Revenue	$0	$0	$0	$0	N/A	N/A
Gross Profit	$0	$0	$0-100.0%	$75K	N/A	N/A
R&D Expenses	$2.3M-65.0%	$6.7M+31825.3%	$21K	$0	N/A	N/A
SG&A Expenses	$946K-7.9%	$1.0M-66.4%	$3.1M-78.4%	$14.1M	N/A	N/A
Operating Income	-$10.1M+53.2%	-$21.5M+37.2%	-$34.2M-143.5%	-$14.0M-20426.0%	-$68K-2963.1%	-$2K
Interest Expense	$396K+267.8%	$108K-50.7%	$218K+16.7%	$187K	N/A	N/A
Income Tax	$0	$0	$0	$0	N/A	N/A
Net Income	-$10.9M+48.9%	-$21.3M+43.4%	-$37.6M-179.4%	-$13.4M+22.2%	-$17.3M-773390.4%	-$2K
EPS (Diluted)	$-5.65+65.9%	$-16.56-529.7%	$-2.63-113.8%	$-1.23	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Revenue	$237K+18.3%	$201K+219.2%	$63K	N/A	$0	$0	$0	N/A
Cost of Revenue	$45K0.0%	$45K0.0%	$45K	N/A	$0	$0	$0	N/A
Gross Profit	$192K+23.6%	$156K+777.8%	$18K	N/A	$0	$0	$0	N/A
R&D Expenses	$587K+102.3%	$290K+235.0%	$87K	N/A	$812K+103.5%	$399K-48.7%	$777K	N/A
SG&A Expenses	$201K-61.8%	$527K+95.9%	$269K	N/A	$173K-27.6%	$239K+38.5%	$173K	N/A
Operating Income	-$2.5M+45.2%	-$4.5M-11.4%	-$4.1M	N/A	-$2.1M+24.3%	-$2.8M+3.2%	-$2.9M	N/A
Interest Expense	$63K-7.6%	$68K-5.2%	$71K	N/A	$51K-22.9%	$66K-67.1%	$201K	N/A
Income Tax	$0	$0	$0	N/A	$0	$0	$0	N/A
Net Income	-$2.9M+33.1%	-$4.3M-26.7%	-$3.4M	N/A	-$1.8M+39.7%	-$3.0M-1.1%	-$3.0M	N/A
EPS (Diluted)	$-0.58	$-1.17-5.4%	$-1.11	N/A	$-0.05+37.5%	$-0.080.0%	$-0.08	N/A

COEPW Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$8.9M+94.9%	$4.6M-42.3%	$7.9M+17.0%	$6.8M-91.2%	$76.7M+44617.2%	$172K
Current Assets	$1.1M-39.9%	$1.7M-55.6%	$3.9M+80.9%	$2.2M+127.3%	$959K+189800.8%	$505
Cash & Equivalents	$533K-63.7%	$1.5M-61.2%	$3.8M+837.6%	$404K-55.4%	$907K+179540.4%	$505
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$0	$0-100.0%	$8K	$0	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$5.0M+34.2%	$3.8M+8.5%	$3.5M-21.6%	$4.4M-94.6%	$81.9M+52420.0%	$156K
Current Liabilities	$4.5M+51.0%	$3.0M+37.6%	$2.2M-21.4%	$2.8M+55198.8%	$5K-96.8%	$156K
Long-Term Debt	$150K0.0%	$150K0.0%	$150K-90.9%	$1.6M	N/A	N/A
Total Equity	$3.4M+315.5%	$814K-81.7%	$4.5M+89.5%	$2.4M+145.7%	-$5.1M-32874.8%	$16K
Retained Earnings	-$98.0M-12.2%	-$87.4M-32.2%	-$66.1M-139.9%	-$27.6M-25.1%	-$22.0M-236506.9%	-$9K

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Total Assets	$14.2M+16.3%	$12.2M-9.4%	$13.5M+51.0%	$8.9M-0.5%	$9.0M+113.3%	$4.2M+7.8%	$3.9M-14.8%	$4.6M
Current Assets	$6.0M+62.1%	$3.7M-20.6%	$4.7M+342.4%	$1.1M-23.0%	$1.4M-31.5%	$2.0M+44.3%	$1.4M-21.1%	$1.7M
Cash & Equivalents	$4.9M+145.8%	$2.0M-53.2%	$4.3M+701.0%	$533K-53.2%	$1.1M-26.9%	$1.6M+51.1%	$1.0M-29.9%	$1.5M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$83K+175.0%	$30K	N/A	$0	N/A	N/A	N/A	$0
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$3.3M-36.1%	$5.1M-14.7%	$6.0M+18.8%	$5.0M+26.9%	$4.0M-11.9%	$4.5M-10.5%	$5.0M+34.0%	$3.8M
Current Liabilities	$2.7M-39.5%	$4.5M-20.8%	$5.7M+25.2%	$4.5M+31.2%	$3.4M-5.1%	$3.6M-15.7%	$4.3M+43.9%	$3.0M
Long-Term Debt	$150K0.0%	$150K	N/A	$150K0.0%	$150K0.0%	$150K0.0%	$150K0.0%	$150K
Total Equity	$10.4M+70.0%	$6.1M-5.9%	$6.5M+91.6%	$3.4M-29.9%	$4.8M+1190.2%	-$443K+61.2%	-$1.1M-240.1%	$814K
Retained Earnings	-$108.4M-2.3%	-$106.0M-4.3%	-$101.7M-3.7%	-$98.0M-3.0%	-$95.2M-2.0%	-$93.4M-3.4%	-$90.4M-3.4%	-$87.4M

COEPW Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$6.6M+8.2%	-$7.2M-86.8%	-$3.9M+13.7%	-$4.5M-3780.4%	-$116K-6385.1%	-$2K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$0	$0	$0+100.0%	-$1.8M+97.7%	-$75.8M	N/A
Financing Cash Flow	$5.7M+16.2%	$4.9M-10.4%	$5.5M-33.2%	$8.2M-89.3%	$76.8M+3353870.0%	$2K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	$247K	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Operating Cash Flow	-$2.2M+10.2%	-$2.4M-1.3%	-$2.4M-64.7%	-$1.4M+24.1%	-$1.9M-33.5%	-$1.4M+25.5%	-$1.9M-12.3%	-$1.7M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$0	$0	$0-100.0%	$100K	$0	$0+100.0%	-$100K	$0
Financing Cash Flow	$5.1M+3947.9%	$125K-97.9%	$6.1M+733.6%	$732K-50.4%	$1.5M-24.1%	$1.9M+24.4%	$1.6M-10.8%	$1.8M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

COEPW Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	100.0%	N/A	N/A
Operating Margin	N/A	N/A	N/A	-18727.9%	N/A	N/A
Net Margin	N/A	N/A	N/A	-17932.4%	N/A	N/A
Return on Equity	-321.6%+2291.1pp	-2612.7%-1769.0pp	-843.7%-271.6pp	-572.2%	N/A	-14.2%
Return on Assets	-122.1%+343.1pp	-465.2%+9.4pp	-474.7%-275.9pp	-198.8%-176.3pp	-22.5%-21.2pp	-1.3%
Current Ratio	0.23-0.4	0.59-1.2	1.81+1.0	0.79-191.0	191.80+191.8	0.00
Debt-to-Equity	0.04-0.1	0.18+0.2	0.03-0.7	0.70+16.6	-15.91-25.8	9.93
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Gross Margin	81.0%+3.5pp	77.5%+49.3pp	28.2%	N/A	N/A	N/A	N/A	N/A
Operating Margin	-1043.2%+1209.7pp	-2252.9%+4199.6pp	-6452.6%	N/A	N/A	N/A	N/A	N/A
Net Margin	-1220.8%+939.1pp	-2159.9%+3281.0pp	-5440.9%	N/A	N/A	N/A	N/A	N/A
Return on Equity	-28.0%+43.1pp	-71.1%-18.3pp	-52.8%	N/A	-37.9%	N/A	N/A	N/A
Return on Assets	-20.4%+15.1pp	-35.5%-10.1pp	-25.4%	N/A	-20.4%+51.9pp	-72.3%+4.8pp	-77.1%	N/A
Current Ratio	2.21+1.4	0.830.0	0.82+0.6	0.23-0.2	0.40-0.2	0.55+0.2	0.32-0.3	0.59
Debt-to-Equity	0.01-0.0	0.02-0.9	0.92+0.9	0.04+0.0	0.03+0.4	-0.34-0.2	-0.13-0.3	0.18
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: The current ratio is below 1.0 (0.23), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Frequently Asked Questions

What is Coeptis Therapeutics Holdings Inc's annual revenue?

Coeptis Therapeutics Holdings Inc (COEPW) reported $0 in total revenue for fiscal year 2024. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Is Coeptis Therapeutics Holdings Inc profitable?

No, Coeptis Therapeutics Holdings Inc (COEPW) reported a net income of -$10.9M in fiscal year 2024.

What is Coeptis Therapeutics Holdings Inc's EBITDA?

Coeptis Therapeutics Holdings Inc (COEPW) had EBITDA of -$9.1M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Coeptis Therapeutics Holdings Inc have?

As of fiscal year 2024, Coeptis Therapeutics Holdings Inc (COEPW) had $533K in cash and equivalents against $150K in long-term debt.

What is Coeptis Therapeutics Holdings Inc's return on equity (ROE)?

Coeptis Therapeutics Holdings Inc (COEPW) has a return on equity of -321.6% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.

What is Coeptis Therapeutics Holdings Inc's operating cash flow?

Coeptis Therapeutics Holdings Inc (COEPW) generated -$6.6M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Coeptis Therapeutics Holdings Inc's total assets?

Coeptis Therapeutics Holdings Inc (COEPW) had $8.9M in total assets as of fiscal year 2024, including both current and long-term assets.

How much does Coeptis Therapeutics Holdings Inc spend on research and development?

Coeptis Therapeutics Holdings Inc (COEPW) invested $2.3M in research and development during fiscal year 2024.

How many shares does Coeptis Therapeutics Holdings Inc have outstanding?

Coeptis Therapeutics Holdings Inc (COEPW) had 2M shares outstanding as of fiscal year 2024.

What is Coeptis Therapeutics Holdings Inc's current ratio?

Coeptis Therapeutics Holdings Inc (COEPW) had a current ratio of 0.23 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.

What is Coeptis Therapeutics Holdings Inc's debt-to-equity ratio?

Coeptis Therapeutics Holdings Inc (COEPW) had a debt-to-equity ratio of 0.04 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Coeptis Therapeutics Holdings Inc's return on assets (ROA)?

Coeptis Therapeutics Holdings Inc (COEPW) had a return on assets of -122.1% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Coeptis Therapeutics Holdings Inc's cash runway?

Based on fiscal year 2024 data, Coeptis Therapeutics Holdings Inc (COEPW) had $533K in cash against an annual operating cash burn of $6.6M. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Coeptis Therapeutics Holdings Inc's Piotroski F-Score?

Coeptis Therapeutics Holdings Inc (COEPW) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Coeptis Therapeutics Holdings Inc's earnings high quality?

Coeptis Therapeutics Holdings Inc (COEPW) has an earnings quality ratio of 0.61x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Coeptis Therapeutics Holdings Inc cover its interest payments?

Coeptis Therapeutics Holdings Inc (COEPW) has an interest coverage ratio of -25.4x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.